Previous 10 | Next 10 |
- Selected targets (Project Cabrillo) represent new therapeutic potential across a broad range of immune and inflammatory diseases - Leveraging Beacon's world-class G protein-coupled receptor (GPCR) discovery platform to augment Arena's robust pipeline SAN DIEGO , Jan. 2, 2020...
Arena Pharmaceuticals, Inc. (ARNA) Evercore HealthCONx Broker Conference Call December 03, 2019, 11:00 ET Company Participants Amit Munshi - President, CEO & Director Conference Call Participants Presentation Operator Unidentified Analyst Arena Pharma. Thanks fo...
SAN DIEGO , Nov. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) was honored by the California Life Sciences Association (CLSA) with the Pantheon 2019 DiNA™ Deal of the Year Award . The Pantheon DiNA Awards are intended to recognize significan...
BeiGene (BGNE) [HK:06160], a Beijing oncology biopharma, announced US approval of its Bruton's tyrosine kinase candidate, Brukinsa™ (zanubrutinib), as a second-line treatment for adult patients with mantle cell lymphoma (see story ). Brukinsa is the first BeiGene-discovered product to ...
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that t...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Buy rating and $110 (21% upside) price target at BofA Merrill Lynch. More news on: Alnylam Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., National Vision Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA) Q3 2019 Earnings Call Nov 7, 2019 , 4:30 p.m. ET Operator Continue reading
Some biotech stocks might be struggling in 2019, but not Arena Pharmaceuticals (NASDAQ: ARNA) . Its share price is up over 20% so far this year. However, that's a lot less than this summer when Arena's shares were up more than 60%. Arena announced its third-quarter results after the m...
Arena Pharmaceuticals, Inc. (ARNA) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Kevin Lind – Chief Financial Officer Amit Munshi – President and Chief Executive Officer Preston Klassen – Head-Research and Development Co...
Arena Pharmaceuticals (NASDAQ: ARNA ): Q3 GAAP EPS of -$1.46 misses by $0.14 . Revenue of $1.35M (-62.2% Y/Y) misses by $0.71M . Press Release More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...